IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i2p1081-d1028429.html
   My bibliography  Save this article

Early Stage Combination Treatment with Methylprednisolone Pulse and Remdesivir for Severe COVID-19 Pneumonia

Author

Listed:
  • Claudio Mastruzzo

    (Unit of Respiratory Diseases, Department of Medicine, Garibaldi Hospital, 95124 Catania, Italy)

  • Elena Commodari

    (Department of Educational Sciences, University of Catania, 95124 Catania, Italy)

  • Umberto Grasso

    (Unit of Internal Medicine, Department of Medicine, Garibaldi Hospital, 95124 Catania, Italy)

  • Valentina Lucia La Rosa

    (Department of Educational Sciences, University of Catania, 95124 Catania, Italy)

  • Daniela Balsamo

    (Unit of Internal Medicine, Department of Medicine, Garibaldi Hospital, 95124 Catania, Italy)

  • Cristina Circo

    (Unit of Respiratory Diseases, Department of Medicine, Garibaldi Hospital, 95124 Catania, Italy)

  • Rosario Oliveri

    (Unit of Respiratory Diseases, Department of Medicine, Garibaldi Hospital, 95124 Catania, Italy)

Abstract

Background: This study evaluated the clinical outcomes of patients with severe COVID-19 pneumonia treated with remdesivir plus standard corticosteroid treatment (SCT) or with remdesivir plus high-dose corticosteroid pulse therapy (HDCPT). Methods: One hundred and two patients with severe COVID-19 pneumonia and respiratory failure were included. The patients were divided into two cohorts. The first comprised patients who received remdesivir and SCT, consisting of 6 mg dexamethasone daily for up to 10 days or until hospital discharge. The second included patients who received remdesivir and HDCPT, composed of 250 mg iv of methylprednisolone for three days, followed by a slow reduction in the dose of steroids. The severity of hypoxemia was assessed using the SaO2/FiO2 peripheral oxygen saturation index. Results: 55 received remdesivir plus HDCPT, and 47 received remdesivir plus SCT. Mortality at 30 days was significantly lower among patients who received remdesivir plus HDCPT (4/55) than among those who did not (15/47). In patients who received remdesivir plus HDCPT, 7.3% required invasive mechanical ventilation and admission to the ICU and 36.4% non-invasive ventilation versus 29.8% and 61.7%, respectively, among those treated with remdesivir plus SCT. Remdesivir plus HDCPT induced a significantly faster improvement in the SaO2/FiO2 index. Conclusion: Early combination treatment with remdesivir plus HDCPT reduced in-hospital mortality and the need for admission to the ICU. Furthermore, it improved the SaO2/FiO2 index faster in patients with severe COVID-19 pneumonia.

Suggested Citation

  • Claudio Mastruzzo & Elena Commodari & Umberto Grasso & Valentina Lucia La Rosa & Daniela Balsamo & Cristina Circo & Rosario Oliveri, 2023. "Early Stage Combination Treatment with Methylprednisolone Pulse and Remdesivir for Severe COVID-19 Pneumonia," IJERPH, MDPI, vol. 20(2), pages 1-10, January.
  • Handle: RePEc:gam:jijerp:v:20:y:2023:i:2:p:1081-:d:1028429
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/2/1081/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/20/2/1081/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:2:p:1081-:d:1028429. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.